X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs SUN PHARMA - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD SUN PHARMA LUPIN LTD/
SUN PHARMA
 
P/E (TTM) x 19.8 24.7 80.2% View Chart
P/BV x 2.7 3.6 74.4% View Chart
Dividend Yield % 0.9 0.6 146.6%  

Financials

 LUPIN LTD   SUN PHARMA
EQUITY SHARE DATA
    LUPIN LTD
Mar-17
SUN PHARMA
Mar-17
LUPIN LTD/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,750842 207.8%   
Low Rs1,384572 241.7%   
Sales per share (Unadj.) Rs387.4131.6 294.3%  
Earnings per share (Unadj.) Rs56.632.7 173.2%  
Cash flow per share (Unadj.) Rs76.838.0 202.3%  
Dividends per share (Unadj.) Rs7.503.50 214.3%  
Dividend yield (eoy) %0.50.5 96.7%  
Book value per share (Unadj.) Rs298.9152.7 195.7%  
Shares outstanding (eoy) m451.582,399.26 18.8%   
Bonus/Rights/Conversions ESOPS--  
Price / Sales ratio x4.05.4 75.3%   
Avg P/E ratio x27.721.6 127.9%  
P/CF ratio (eoy) x20.418.6 109.5%  
Price / Book Value ratio x5.24.6 113.2%  
Dividend payout %13.210.7 123.7%   
Avg Mkt Cap Rs m707,5131,696,877 41.7%   
No. of employees `00016.817.5 95.9%   
Total wages/salary Rs m28,49549,023 58.1%   
Avg. sales/employee Rs Th10,418.318,028.3 57.8%   
Avg. wages/employee Rs Th1,697.02,798.8 60.6%   
Avg. net profit/employee Rs Th1,523.04,479.5 34.0%   
INCOME DATA
Net Sales Rs m174,943315,784 55.4%  
Other income Rs m1,0656,232 17.1%   
Total revenues Rs m176,008322,016 54.7%   
Gross profit Rs m44,931100,893 44.5%  
Depreciation Rs m9,12212,648 72.1%   
Interest Rs m1,5253,998 38.2%   
Profit before tax Rs m35,34990,479 39.1%   
Minority Interest Rs m-720-   
Prior Period Items Rs m8399 83.1%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m9,78512,116 80.8%   
Profit after tax Rs m25,57578,462 32.6%  
Gross profit margin %25.731.9 80.4%  
Effective tax rate %27.713.4 206.7%   
Net profit margin %14.624.8 58.8%  
BALANCE SHEET DATA
Current assets Rs m119,542329,537 36.3%   
Current liabilities Rs m61,206178,870 34.2%   
Net working cap to sales %33.347.7 69.9%  
Current ratio x2.01.8 106.0%  
Inventory Days Days7679 96.2%  
Debtors Days Days9083 107.9%  
Net fixed assets Rs m131,660204,766 64.3%   
Share capital Rs m9032,399 37.6%   
"Free" reserves Rs m134,073363,997 36.8%   
Net worth Rs m134,976366,397 36.8%   
Long term debt Rs m56,47814,361 393.3%   
Total assets Rs m266,073614,102 43.3%  
Interest coverage x24.223.6 102.3%   
Debt to equity ratio x0.40 1,067.6%  
Sales to assets ratio x0.70.5 127.9%   
Return on assets %10.213.4 75.9%  
Return on equity %18.921.4 88.5%  
Return on capital %19.324.8 77.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m81,88544,118 185.6%   
Fx outflow Rs m21,50624,484 87.8%   
Net fx Rs m60,37819,634 307.5%   
CASH FLOW
From Operations Rs m41,14870,822 58.1%  
From Investments Rs m-25,287-42,216 59.9%  
From Financial Activity Rs m4,332-22,854 -19.0%  
Net Cashflow Rs m20,1936,107 330.7%  

Share Holding

Indian Promoters % 46.6 63.7 73.2%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 5.1 220.3%  
FIIs % 31.9 23.0 138.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 8.3 121.7%  
Shareholders   98,259 133,026 73.9%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   DR. DATSONS LABS  STRIDES SHASUN LTD  FDC LTD.  JUBILANT LIFE SCIENCES  BIOCON LTD  

Compare LUPIN LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Red; PSU & Energy Stocks Decline(01:30 pm)

Indian share markets continued to trade in red during the noon session weak Asian markets. PSU stocks and energy stocks are witnessing majority of the selling activity.

Related Views on News

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Feb 22, 2018 03:37 PM

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

LUPIN LTD 8-QTR ANALYSIS

COMPARE LUPIN LTD WITH

MARKET STATS